Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TIL

Instil Bio Inc

Dec 13 • 04:00PM ET

21.97

Dollar change +0.54
Percentage change 2.52	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE ADAP IOVA EDIT CRSP PSTX BLUE BMRN SRPT CLLS

| Held by: VTI VXF DFAC IWC DFAT DFAS AVSC DFSU DFAU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.56	Insider Own	53.24%	Shs Outstand	6.53M	Perf Week	-20.89%
Market Cap	143.37M	Forward P/E	-	EPS next Y	-15.18	Insider Trans	0.00%	Shs Float	3.05M	Perf Month	-30.34%
Income	-75.17M	PEG	-	EPS next Q	-3.01	Inst Own	33.41%	Short Float	7.99%	Perf Quarter	-65.84%
Sales	0.00M	P/S	-	EPS this Y	-23.21%	Inst Trans	94.04%	Short Ratio	0.95	Perf Half Y	110.44%
Book/sh	27.02	P/B	0.81	EPS next Y	-21.53%	ROA	-24.53%	Short Interest	0.24M	Perf Year	242.21%
Cash/sh	18.44	P/C	1.19	EPS next 5Y	-	ROE	-36.63%	52W Range	6.37 - 92.00	Perf YTD	188.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-120.38%	ROI	-28.92%	52W High	-76.12%	Beta	1.63
Dividend TTM	-	Quick Ratio	12.90	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	244.90%	ATR (14)	3.35
Dividend Ex-Date	-	Current Ratio	12.90	EPS Y/Y TTM	61.87%	Oper. Margin	-	RSI (14)	37.93	Volatility	10.88% 12.47%
Employees	49	Debt/Eq	0.48	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	145.00
Option/Short	No / Yes	LT Debt/Eq	0.47	EPS Q/Q	65.87%	Payout	-	Rel Volume	0.28	Prev Close	21.43
Sales Surprise	-100.00%	EPS Surprise	-21.00%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	257.05K	Price	21.97
SMA20	-14.75%	SMA50	-29.24%	SMA200	5.91%	Trades		Volume	73,189	Change	2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-24	Initiated	JMP Securities	Mkt Perform
Apr-12-24	Downgrade	Jefferies	Buy → Hold	$5 → $11
Nov-01-22	Downgrade	Truist	Buy → Hold	$16 → $6
Nov-01-22	Downgrade	Cowen	Outperform → Market Perform
Aug-13-21	Initiated	Robert W. Baird	Outperform	$34
Apr-13-21	Initiated	Truist	Buy	$32
Apr-13-21	Initiated	Morgan Stanley	Equal-Weight	$24
Apr-13-21	Initiated	Cowen	Outperform

Nov-13-24 07:00AM	Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.51%
Oct-23-24 01:01AM	Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc (GuruFocus.com) -5.27%
Sep-27-24 09:43PM	BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc (GuruFocus.com)
07:03PM	Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc (GuruFocus.com)
Sep-25-24 04:56AM	2 Stocks Up Over 700% in 2024 That Could Soar Even Further (Motley Fool)
04:24AM	Loading…
Sep-17-24 04:24AM	Here's Why Everyone's Talking About Summit Therapeutics (Motley Fool)
Sep-16-24 06:00AM	Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (GlobeNewswire) -23.91%
Sep-14-24 04:56AM	Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? (Motley Fool)
Aug-13-24 10:53PM	TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 (InvestorPlace)
05:00PM	Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-24 06:00AM	Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody (GlobeNewswire)
Jul-12-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +31.13%
May-10-24 01:54PM	TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-24 12:00PM	What Makes Instil Bio (TIL) a New Buy Stock (Zacks)
10:52PM	Loading…
Mar-21-24 10:52PM	TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023 (InvestorPlace)
05:00PM	Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-18-24 12:28PM	Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why (Zacks) +6.49%
Jan-16-24 08:00AM	Instil Bio Announces Strategic Update (GlobeNewswire)
Dec-13-23 10:52AM	TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023 (InvestorPlace)
10:51AM	TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023 (InvestorPlace)
Dec-05-23 05:00PM	Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split (GlobeNewswire)
Nov-13-23 05:00PM	Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.42%
Nov-06-23 07:00AM	Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting (GlobeNewswire)
Aug-31-23 09:35AM	After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL) (Zacks)
Aug-14-23 07:00AM	Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.18%
Jun-26-23 04:38PM	Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference (GlobeNewswire)
May-11-23 07:00AM	Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -7.42%
Mar-31-23 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-22-23 07:57AM	Heres Why Instil Bio (TIL) Declined in Q4 (Insider Monkey) -5.57%
07:04AM	Loading…
Feb-17-23 07:04AM	Private equity firms account for 39% of Instil Bio, Inc.'s (NASDAQ:TIL) ownership, while institutions account for 34% (Simply Wall St.)
Jan-31-23 05:00PM	Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site (GlobeNewswire) +6.52%
Jan-09-23 12:30PM	Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers (Benzinga) +5.73%
07:00AM	Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer (GlobeNewswire)
Dec-13-22 09:35AM	Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) (Zacks) -16.25%
Dec-09-22 09:35AM	Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) (Zacks)
Dec-08-22 11:04AM	Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees (Benzinga) -19.67%
07:00AM	Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce (GlobeNewswire)
Nov-14-22 04:07PM	Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.74%
Nov-08-22 07:00AM	Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-31-22 10:40AM	Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials (Benzinga) -37.14%
08:52AM	Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials (MarketWatch)
07:00AM	Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing (GlobeNewswire)
Oct-18-22 07:00AM	Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FR), in Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-19-22 07:20AM	Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -7.07%
Sep-09-22 07:00AM	Instil Bio to Present at Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-06-22 07:00AM	Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer (GlobeNewswire)
Aug-12-22 07:00AM	Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-22 08:21AM	Will Instil Bio (NASDAQ:TIL) Spend Its Cash Wisely? (Simply Wall St.)
Jul-11-22 05:28PM	Instil Bio Life Sciences Campus in Tarzana gets $85 million loan for expansion (American City Business Journals) -6.27%
May-27-22 07:00AM	Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment (GlobeNewswire) -24.34%
May-18-22 07:00AM	Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire) -5.09%
May-16-22 07:00AM	Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.70%
Mar-07-22 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-22 07:00AM	Instil Bio to Present at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Nov-15-21 07:00AM	Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-10-21 11:28AM	Was The Smart Money Right About Instil Bio, Inc. (TIL)? (Insider Monkey)
Nov-08-21 08:05AM	Instil Bio to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Sep-16-21 07:00AM	Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress (GlobeNewswire)
Sep-15-21 04:27PM	Why Iovance Is Up Nearly 11% Today (Motley Fool) +16.55%
Sep-13-21 07:00AM	Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma (GlobeNewswire)
Sep-02-21 07:00AM	Instil Bio to Present at Upcoming Investor Conferences in September (GlobeNewswire) +7.49%
Aug-12-21 07:00AM	Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-19-21 02:34PM	Do Hedge Funds Love Instil Bio, Inc. (TIL)? (Insider Monkey)
Jun-21-21 10:06AM	Are Institutions Heavily Invested In Instil Bio, Inc.'s (NASDAQ:TIL) Shares? (Simply Wall St.)
Jun-01-21 07:00AM	Instil Bio to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 07:00AM	Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.83%
Apr-29-21 08:45AM	At a Recent Cancer Research Conference, Instil Bio Stole the Show (Motley Fool) +6.10%
Apr-27-21 07:00AM	Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma (GlobeNewswire)
Apr-12-21 07:18AM	Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-23-21 05:00PM	Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -6.95%
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading (Barrons.com)
Mar-18-21 08:26PM	Instil Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TIL

Instil Bio Inc

Upgrade your FINVIZ experience